Amphastar Pharmaceuticals Inc (AMPH)
38.09
-0.47
(-1.22%)
USD |
NASDAQ |
Jul 05, 10:59
Amphastar Pharmaceuticals Research and Development Expense (TTM): 70.97M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 70.97M |
| December 31, 2023 | 73.74M |
| September 30, 2023 | 70.56M |
| June 30, 2023 | 72.41M |
| March 31, 2023 | 78.36M |
| December 31, 2022 | 74.77M |
| September 30, 2022 | 74.82M |
| June 30, 2022 | 67.07M |
| March 31, 2022 | 62.39M |
| December 31, 2021 | 60.93M |
| September 30, 2021 | 61.78M |
| June 30, 2021 | 68.66M |
| March 31, 2021 | 66.69M |
| December 31, 2020 | 67.23M |
| September 30, 2020 | 68.74M |
| June 30, 2020 | 69.70M |
| March 31, 2020 | 69.55M |
| December 31, 2019 | 68.85M |
| September 30, 2019 | 65.94M |
| June 30, 2019 | 58.68M |
| March 31, 2019 | 58.14M |
| Date | Value |
|---|---|
| December 31, 2018 | 57.56M |
| September 30, 2018 | 52.22M |
| June 30, 2018 | 50.95M |
| March 31, 2018 | 46.22M |
| December 31, 2017 | 43.44M |
| September 30, 2017 | 44.66M |
| June 30, 2017 | 44.30M |
| March 31, 2017 | 44.17M |
| December 31, 2016 | 41.52M |
| September 30, 2016 | 37.78M |
| June 30, 2016 | 39.18M |
| March 31, 2016 | 39.31M |
| December 31, 2015 | 37.27M |
| September 30, 2015 | 36.49M |
| June 30, 2015 | 33.96M |
| March 31, 2015 | 29.22M |
| December 31, 2014 | 28.87M |
| September 30, 2014 | 28.07M |
| June 30, 2014 | 28.53M |
| March 31, 2014 | 30.32M |
| December 31, 2013 | 33.02M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
60.93M
Minimum
Dec 2021
78.36M
Maximum
Mar 2023
69.11M
Average
68.85M
Median
Dec 2019
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 9.851B |
| Biogen Inc | 2.344B |
| Pfizer Inc | 10.67B |
| Anavex Life Sciences Corp | 38.28M |
| Corvus Pharmaceuticals Inc | 16.01M |